<DOC>
	<DOCNO>NCT00547482</DOCNO>
	<brief_summary>The main purpose research study investigate whether TANTALUS II System effective improve glycemic ( blood sugar ) control subject type 2 diabetes ( high blood sugar ) overweight . The research also evaluate impact weight loss study health condition related obesity . This research study involve experimental system . The experimental system TANTALUS System , consist implantable portion include implantable pulse generator ( IPG ) three pair implantable lead . There also three external part ( item use outside body ) : programmer , charger , Patient Wand .</brief_summary>
	<brief_title>The TANTALUS® II System Treatment Type 2 Diabetes : A Randomized Study</brief_title>
	<detailed_description>This randomize , double-blind control , multi-center study . Three hundred ( 300 ) subject type 2 diabetes range low BMI BMI 45 ( BMI ≥ 28 ≤ 45 ) enrol . The duration subject participation main portion study include initial study study extension period expect approximately 12 month . Upon completion period , subject TANTALUS device shall continue follow clinically six-month interval ( Safety Monitoring Period ) FDA make determination regard safety efficacy device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Body mass index ( BMI ) ≥ 28 ≤ 45 ( kg/m2 ) 2 . Type 2 diabetes &gt; 6 month 3 . Type 2 diabetic subject treat oral antidiabetic 4 . Stable antidiabetic medication ≥3 month prior enrollment , six month TZD 5 . HbA1c ≥7.5 % ≤ 9.5 % Visit 1 , subject T2DM duration &gt; 10 yr HbA1c ≥7.5 % ≤ 9.0 6 . Stable HbA1c , Stable weight , stable treatment antihypertensive and/or lipid lower medication 7 . Fasting blood glucose &gt; 120 &lt; 240 mg/dl Visit 1 , subject T2DM duration &gt; 10 yr &gt; 120 ≤180 . 8 . Women childbearing potential must agree use adequate birth control methods 9 . Stable weight significant change ( variation &lt; 5 % ) last 6 month 10 . Willingness perform least 4 capillary blood glucose test per day twice week duration study 11 . Willingness refrain use prescription , counter herbal weight loss product duration trial 12 . Ability willingness perform require study data collection procedure adhere operate requirement TANTALUS II System 13 . Alert , mentally competent , 14 . Able provide voluntary inform consent HIPAA Authorization 1 . Receiving insulin therapy 2 . Taking GLP1 , Amylin treatment ( Byetta , Symlin ) 3 . Blood pressure level &gt; 180/100 4 . Patients EF le 35 % ( obtain within last 6 month ) indicate ICD ; echocardiogram outdated unavailable , procedure do 5 . Taking medication know affect gastric motility narcotic ( chronic use ) anticholinergics/antispasmodics 6 . Use prescription , counter herbal weight loss product obesity drug two month prior enrollment 7 . Experiencing severe progress diabetic complication ( i.e . retinopathy stabilize , nephropathy macroalbuminuria ) 8 . Prior wound heal problem due Staphylococcus Candida 9 . Prior bariatric surgery 10 . History pancreatitis 11 . History peptic ulcer disease within 5 year enrollment 12 . Diagnosed gastroparesis 13 . Use active medical device ( either implantable external ) ICD , pacemaker , neurostimulator ( either implant worn ) . Subjects use external active device able willing avoid use device study may enrol . 14 . Cardiac history physician feel exclude patient 15 . Use another investigational device agent 30 day prior enrollment 16 . A history lifethreatening disease within 5 year enrollment 17 . Any additional condition ( ) Investigator 's opinion would warrant exclusion study prevent subject completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Overweight</keyword>
	<keyword>Obese</keyword>
</DOC>